An investing take on Novo Nordisk shares after a 75% drop, weighing whether the Wegovy maker is a bargain or a trap.
Recap by typeshit. Post by Investseekers on X.
An international food and agribusiness expert links growing interest in fibre to the spread of GLP-1 drugs. Details are thin beyond the claim itself.
Early trial results suggest the shot could one day help people hold onto weight loss after they come off GLP-1 drugs.
Bodybuilder Sam Sulek gives his take on peptides in a short clip from Chris Williamson's show. His views are his own, not medical guidance.
Superpower frames apitegromab's FDA approval as a big step and ties it to concern that GLP-1 users can lose a lot of muscle along with fat.
Researchers are looking into whether GLP-1 drugs could have an effect on biological aging. The share gives few details, so tap through for what the work actually shows.
A short social post says researchers are examining a possible link between GLP-1 drugs and slower aging. No study or data is named, so treat it as early talk.
Loading…